Oral Medicines for Diabetes Market Report – Research, Industry Analysis Reports and Market Demands

Global Oral Medicines for Diabetes Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Oral Medicines for Diabetes Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Biguanides
- 1.3.3 Sulfonylureas
- 1.3.4 Meglitinides
- 1.3.5 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
- 1.3.6 SGLT2 Inhibitors
- 1.3.7 Thiazolidinediones
- 1.3.8 Alpha-Glucosidase Inhibitors
- 1.3.9 Other
1.4 Market Analysis by Application
- 1.4.1 Overview: Global Oral Medicines for Diabetes Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Hospital
- 1.4.3 Clinic
- 1.4.4 Other
1.5 Global Oral Medicines for Diabetes Market Size & Forecast
- 1.5.1 Global Oral Medicines for Diabetes Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Oral Medicines for Diabetes Sales Quantity (2021-2032)
- 1.5.3 Global Oral Medicines for Diabetes Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: Oral Medicines for Diabetes by Manufacturer

3.1 Global Oral Medicines for Diabetes Sales Quantity by Manufacturer (2021-2026)
3.2 Global Oral Medicines for Diabetes Revenue by Manufacturer (2021-2026)
3.3 Global Oral Medicines for Diabetes Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Oral Medicines for Diabetes by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Oral Medicines for Diabetes Manufacturer Market Share in 2025
- 3.4.3 Top 6 Oral Medicines for Diabetes Manufacturer Market Share in 2025
3.5 Oral Medicines for Diabetes Market: Overall Company Footprint Analysis
- 3.5.1 Oral Medicines for Diabetes Market: Region Footprint
- 3.5.2 Oral Medicines for Diabetes Market: Company Product Type Footprint
- 3.5.3 Oral Medicines for Diabetes Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Oral Medicines for Diabetes Market Size by Region
- 4.1.1 Global Oral Medicines for Diabetes Sales Quantity by Region (2021-2032)
- 4.1.2 Global Oral Medicines for Diabetes Consumption Value by Region (2021-2032)
- 4.1.3 Global Oral Medicines for Diabetes Average Price by Region (2021-2032)
4.2 North America Oral Medicines for Diabetes Consumption Value (2021-2032)
4.3 Europe Oral Medicines for Diabetes Consumption Value (2021-2032)
4.4 Asia-Pacific Oral Medicines for Diabetes Consumption Value (2021-2032)
4.5 South America Oral Medicines for Diabetes Consumption Value (2021-2032)
4.6 Middle East & Africa Oral Medicines for Diabetes Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global Oral Medicines for Diabetes Sales Quantity by Type (2021-2032)
5.2 Global Oral Medicines for Diabetes Consumption Value by Type (2021-2032)
5.3 Global Oral Medicines for Diabetes Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global Oral Medicines for Diabetes Sales Quantity by Application (2021-2032)
6.2 Global Oral Medicines for Diabetes Consumption Value by Application (2021-2032)
6.3 Global Oral Medicines for Diabetes Average Price by Application (2021-2032)

7 North America

7.1 North America Oral Medicines for Diabetes Sales Quantity by Type (2021-2032)
7.2 North America Oral Medicines for Diabetes Sales Quantity by Application (2021-2032)
7.3 North America Oral Medicines for Diabetes Market Size by Country
- 7.3.1 North America Oral Medicines for Diabetes Sales Quantity by Country (2021-2032)
- 7.3.2 North America Oral Medicines for Diabetes Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe Oral Medicines for Diabetes Sales Quantity by Type (2021-2032)
8.2 Europe Oral Medicines for Diabetes Sales Quantity by Application (2021-2032)
8.3 Europe Oral Medicines for Diabetes Market Size by Country
- 8.3.1 Europe Oral Medicines for Diabetes Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Oral Medicines for Diabetes Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific Oral Medicines for Diabetes Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Oral Medicines for Diabetes Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Oral Medicines for Diabetes Market Size by Region
- 9.3.1 Asia-Pacific Oral Medicines for Diabetes Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Oral Medicines for Diabetes Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America Oral Medicines for Diabetes Sales Quantity by Type (2021-2032)
10.2 South America Oral Medicines for Diabetes Sales Quantity by Application (2021-2032)
10.3 South America Oral Medicines for Diabetes Market Size by Country
- 10.3.1 South America Oral Medicines for Diabetes Sales Quantity by Country (2021-2032)
- 10.3.2 South America Oral Medicines for Diabetes Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa Oral Medicines for Diabetes Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Oral Medicines for Diabetes Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Oral Medicines for Diabetes Market Size by Country
- 11.3.1 Middle East & Africa Oral Medicines for Diabetes Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Oral Medicines for Diabetes Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 Oral Medicines for Diabetes Market Drivers
12.2 Oral Medicines for Diabetes Market Restraints
12.3 Oral Medicines for Diabetes Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Oral Medicines for Diabetes and Key Manufacturers
13.2 Manufacturing Costs Percentage of Oral Medicines for Diabetes
13.3 Oral Medicines for Diabetes Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Oral Medicines for Diabetes Typical Distributors
14.3 Oral Medicines for Diabetes Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Oral Medicines for Diabetes market size was valued at US$ 79490 million in 2025 and is forecast to a readjusted size of US$ 158010 million by 2032 with a CAGR of 10.4% during review period.
Oral medications for diabetes are medications that are taken by mouth to manage blood sugar levels in people with type 2 diabetes.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Oral Medicines for Diabetes market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Oral Medicines for Diabetes market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Oral Medicines for Diabetes market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Oral Medicines for Diabetes market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Oral Medicines for Diabetes market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Oral Medicines for Diabetes
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Oral Medicines for Diabetes market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Merck, Novartis, Huadong Medicine, Sanofi, Novo Nordisk, Servier, Takeda Pharmaceutical, Luye Pharmaceutical, Taiji Group, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Oral Medicines for Diabetes market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Biguanides
Sulfonylureas
Meglitinides
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
SGLT2 Inhibitors
Thiazolidinediones
Alpha-Glucosidase Inhibitors
Other
Market segment by Application
Hospital
Clinic
Other
Major players covered
Bayer
Merck
Novartis
Huadong Medicine
Sanofi
Novo Nordisk
Servier
Takeda Pharmaceutical
Luye Pharmaceutical
Taiji Group
CR Double-Crane
AstraZeneca
Boehringer Ingelheim
Qilu Pharmaceutical
Jiangsu Deyuan Pharmaceutical
CTTQ
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Oral Medicines for Diabetes product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Oral Medicines for Diabetes, with price, sales quantity, revenue, and global market share of Oral Medicines for Diabetes from 2021 to 2026.
Chapter 3, the Oral Medicines for Diabetes competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Oral Medicines for Diabetes breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Oral Medicines for Diabetes market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Oral Medicines for Diabetes.
Chapter 14 and 15, to describe Oral Medicines for Diabetes sales channel, distributors, customers, research findings and conclusion.

Buy now